Related Experiment Video

Updated: Jul 19, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice

Xi Hu1, Ying Feng, Yu Shen

  • 1Shanghai Institute of Materia Medica, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China.

Acta Pharmacologica Sinica
|September 30, 2006
PubMed
Abstract

Insights

The novel compound T33, a peroxisome proliferator-activated receptor (PPAR) gamma/alpha dual agonist, demonstrated significant antidiabetic effects in obese mice. T33 improved glucose control and insulin sensitivity, showing potential for type 2 diabetes treatment.

Area of Science:

  • Pharmacology
  • Metabolic Diseases
  • Endocrinology

Background:

  • Obesity and type 2 diabetes are complex metabolic disorders.
  • Insulin resistance is a key feature of type 2 diabetes.
  • Peroxisome proliferator-activated receptors (PPARs) are targets for diabetes treatment.

Purpose of the Study:

  • To evaluate the antidiabetic efficacy of T33, a new non-thiazolidinedione (TZD) PPAR gamma/alpha dual agonist.
  • To investigate the effects of T33 on glucose metabolism and insulin sensitivity in a mouse model of obesity and diabetes.

Main Methods:

  • Obese (ob/ob) mice were treated with T33 (4 or 8 mg/kg) or vehicle for 20 days.
  • Glucose levels, oral glucose tolerance tests (OGTT), and insulin tolerance tests (ITT) were assessed.
  • Serum and tissue levels of insulin, triglycerides, and free fatty acids (FFA) were measured.

Main Results:

  • T33 treatment significantly reduced hyperglycemia, hyperinsulinemia, and hyperlipidemia in ob/ob mice.
  • T33 ameliorated insulin resistance, as evidenced by improved OGTT and ITT results.
  • T33 decreased intramuscular triglyceride content without affecting liver triglyceride levels, unlike rosiglitazone.

Conclusions:

  • T33 exhibits significant antidiabetic and insulin-sensitizing properties in diet-induced obese mice.
  • As a PPAR gamma/alpha dual agonist, T33 holds promise as a novel therapeutic agent for type 2 diabetes.
  • T33 offers a potential alternative with a distinct metabolic profile compared to existing TZD drugs.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...